Thousands of managed care pharmacy professionals from health plans, PBMs, pharmaceutical manufacturers, and other managed care organizations convened in Houston, TX, from March 31–April 3 for AMCP 2025, the industry’s premier conference.
On April 16, 2025, the Centers for Medicare and Medicaid Services (CMS) issued guidance on CY 2026 Part D Formulary Submissions (Guidance). The Guidance includes important dates related to CY 2026 formulary submissions.
This month, the House and Senate reached an agreement on a concurrent budget resolution, after weeks of back-and-forth negotiations over topline spending and savings numbers.
On April 15, 2025, the Trump administration issued an Executive Order (EO) on prescription drug costs.
On April 7, 2025, the Centers for Medicare and Medicaid Services issued the Calendar Year (CY) 2026 Rate Announcement and Final CY 2026 Part D Redesign Program Instructions.
On April 4, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (Part D Final Rule).
Read the Journal of Managed Care + Specialty Pharmacy (JMCP) April 2025 Issue
On March 27, 2025, the U.S. Department of Health and Human Services (HHS) issued a Fact Sheet: HHS’ Transformation to Make America Healthy Again. The document outlines HHS' restructuring plan as part of an initiative to enhance efficiency and address chronic diseases in America. Key changes include significant personnel reductions and consolidating divisions and offices to streamline operations.
AMCP formed the PAC to support candidates who promote policies that improve the practice of managed care pharmacy. Prescription drug prices consistently rank as a top issue for voters, so it’s important to ensure that the managed care perspective is represented in these policy conversations.
